Literature DB >> 17822802

Formulation of Neulasta (pegfilgrastim).

Deirdre Murphy Piedmonte1, Michael J Treuheit.   

Abstract

Neulasta (pegfilgrastim) is a PEGylated version of its parent molecule NEUPOGEN (Filgrastim). This work describes the formulation development for Neulasta (pegfilgrastim), and the analytical techniques used to monitor degradation during these studies. Stability was assessed as a function of pH, protein concentration, buffer type, tonicity modifiers and surfactant concentration under both accelerated conditions and quiescent long-term storage. The stability of Neulasta (pegfilgrastim) to agitation and successive freeze-thaw cycles was also assessed. Neulasta (pegfilgrastim), at a protein concentration of 10 mg/mL formulated in 10 mM acetate, pH 4.0 with 5% sorbitol and 0.004% polysorbate 20, is stable for two years stored at 2-8 degrees C.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17822802     DOI: 10.1016/j.addr.2007.04.017

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  17 in total

1.  Denaturation of proteins by SDS and tetraalkylammonium dodecyl sulfates.

Authors:  Andrew Lee; Sindy K Y Tang; Charles R Mace; George M Whitesides
Journal:  Langmuir       Date:  2011-08-23       Impact factor: 3.882

Review 2.  Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.

Authors:  Fatemeh Farjadian; Amir Ghasemi; Omid Gohari; Amir Roointan; Mahdi Karimi; Michael R Hamblin
Journal:  Nanomedicine (Lond)       Date:  2018-11-19       Impact factor: 5.307

Review 3.  New agents in HSC mobilization.

Authors:  Mélanie J Domingues; Susan K Nilsson; Benjamin Cao
Journal:  Int J Hematol       Date:  2016-11-30       Impact factor: 2.490

4.  Using hydrogen/deuterium exchange mass spectrometry to study conformational changes in granulocyte colony stimulating factor upon PEGylation.

Authors:  Hui Wei; Joomi Ahn; Ying Qing Yu; Adrienne Tymiak; John R Engen; Guodong Chen
Journal:  J Am Soc Mass Spectrom       Date:  2012-01-07       Impact factor: 3.109

5.  Specific activity of electron-beam synthesis immobilized hyaluronidase on G-CSF induced mobilization of bone marrow progenitor cells.

Authors:  A M Dygai; G N Zyuz'kov; V V Zhdanov; E V Udut; L A Miroshnichenko; E V Simanina; T Yu Khrichkova; M Yu Minakova; P G Madonov
Journal:  Stem Cell Rev Rep       Date:  2013-04       Impact factor: 5.739

Review 6.  Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications.

Authors:  Hui Wei; Jingjie Mo; Li Tao; Reb J Russell; Adrienne A Tymiak; Guodong Chen; Roxana E Iacob; John R Engen
Journal:  Drug Discov Today       Date:  2013-08-06       Impact factor: 7.851

7.  A bioengineered arginine-depleting enzyme as a long-lasting therapeutic agent against cancer.

Authors:  Sai-Fung Chung; Chi-Fai Kim; Suet-Ying Tam; Man-Chung Choi; Pui-Kin So; Kwok-Yin Wong; Yun-Chung Leung; Wai-Hung Lo
Journal:  Appl Microbiol Biotechnol       Date:  2020-03-06       Impact factor: 4.813

Review 8.  Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor.

Authors:  Tara Arvedson; James O'Kelly; Bing-Bing Yang
Journal:  BioDrugs       Date:  2015-06       Impact factor: 5.807

Review 9.  Site-Specific PEGylation of Therapeutic Proteins.

Authors:  Jonathan K Dozier; Mark D Distefano
Journal:  Int J Mol Sci       Date:  2015-10-28       Impact factor: 5.923

Review 10.  Molecular Simulations of PEGylated Biomolecules, Liposomes, and Nanoparticles for Drug Delivery Applications.

Authors:  Hwankyu Lee
Journal:  Pharmaceutics       Date:  2020-06-10       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.